July 1 P&P Quick Takes: FDA guidance on heart failure endpoints; plus upcoming CBER guidances and more

FDA issues draft guidance to spur development of heart failure drugs
FDA issued a draft guidance describing the agency's thinking on clinical endpoints for heart failure drugs that could re-ignite cardiovascular drug development. The guidance noted that effect on symptoms or physical function

Read the full 420 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE